Suppr超能文献

2006年2月至2007年5月美国轮状病毒疫苗接种覆盖率及对免疫实践咨询委员会(ACIP)推荐的疫苗接种计划的依从性

Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule--United States, February 2006-May 2007.

出版信息

MMWR Morb Mortal Wkly Rep. 2008 Apr 18;57(15):398-401.

Abstract

Worldwide, rotavirus is the leading cause of severe gastroenteritis in children aged <5 years. In February 2006, a new human-bovine rotavirus vaccine, RotaTeq (Merck & Co., Inc., Whitehouse Station, New Jersey), was recommended by the Advisory Committee on Immunization Practices (ACIP) for routine vaccination of U.S. infants. Three doses of RotaTeq are recommended at ages 2, 4, and 6 months. The first dose should be administered between ages 6 and 12 weeks, and vaccination should not be initiated for infants aged >12 weeks. Subsequent doses should be administered at 4-10 week intervals, with all doses administered by age 32 weeks. This schedule is consistent with the ages at which RotaTeq was administered during prelicensure trials, and ACIP has recommended that RotaTeq only be administered at the ages for which safety and efficacy data are available. In 1999, a previous rhesus-human rotavirus vaccine, RotaShield (Wyeth Laboratories, Inc., Marietta, Pennsylvania), was withdrawn voluntarily from the U.S. market by the manufacturer because it was associated with intussusception, a form of bowel obstruction. The greatest risk for intussusception was noted after the first dose of RotaShield. Data from a large-scale, prelicensure safety trial and postlicensure monitoring do not indicate an association between the current RotaTeq vaccine and intussusception. CDC assessed rotavirus vaccination coverage among U.S. infants during February 2006-May 2007 and examined adherence to the ACIP-recommended vaccination schedule. This report summarizes the results of that assessment, which indicated that, by May 15, 2007, nearly half of infants aged 3 months had received 1 dose of rotavirus vaccine, with the majority of doses administered according to ACIP recommendations. Health-care providers should remain vigilant in following the ACIP-recommended vaccination schedule for rotavirus vaccine.

摘要

在全球范围内,轮状病毒是5岁以下儿童严重胃肠炎的主要病因。2006年2月,免疫实践咨询委员会(ACIP)建议使用一种新的人-牛轮状病毒疫苗——Rotateq(默克公司,新泽西州怀特豪斯站)对美国婴儿进行常规接种。建议在2、4和6月龄时接种三剂Rotateq。第一剂应在6至12周龄之间接种,对于12周龄以上的婴儿不应开始接种。后续剂量应每隔4至10周接种,所有剂量均应在32周龄前接种。该接种程序与Rotateq在获得许可前试验期间的接种年龄一致,ACIP建议仅在有安全性和有效性数据的年龄接种Rotateq。1999年,先前的一种恒河猴-人轮状病毒疫苗——Rotashield(惠氏实验室公司,宾夕法尼亚州玛丽埃塔)被制造商自愿从美国市场撤回,因为它与肠套叠(一种肠梗阻形式)有关。接种第一剂Rotashield后肠套叠风险最高。一项大规模的许可前安全性试验和许可后监测的数据未表明目前的Rotateq疫苗与肠套叠之间存在关联。美国疾病控制与预防中心(CDC)评估了2006年2月至2007年5月期间美国婴儿的轮状病毒疫苗接种覆盖率,并检查了对ACIP推荐接种程序的依从性。本报告总结了该评估结果,结果表明,截至2007年5月15日,近一半3月龄婴儿接种了1剂轮状病毒疫苗,大多数剂量的接种符合ACIP的建议。医疗保健提供者应继续严格遵循ACIP推荐的轮状病毒疫苗接种程序。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验